Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
Matia MartucciAndrea Maurizio FerrantiFrancesco SchimpernaAmato InfanteFrancesca MagnaniAlessandro OliviQuintino Giorgio D'AlessandrisMarco GessiSilvia ChiesaCiro MazzarellaRosellina RussoCarolina GiordanoSimona GaudinoPublished in: Neuroradiology (2023)
Our results suggest that rCBVmax of the glioblastoma at diagnosis could serve as a non-invasive biomarker of treatment response to regorafenib in patients with rGB.